About targeted protein degradation
Targeted protein degradation harnesses the body’s natural machinery to break down proteins into smaller molecules (“proteolysis”). This process can be induced by a special type of small molecules known as “molecular glues”. Bristol Myers Squibb has a comprehensive library of such molecular glues based on the cereblon E3 ligase modulator (“CELMoD®”). By specifically altering the protein-binding properties of cereblon, CELMoD® agents can promote the targeted degradation of disease-causing proteins.
About EVOpanOmics and EVOpanHunter
EVOpanOmics and EVOpanHunter are two of the building blocks of Evotec’s strategic framework, Action Plan 2025: “the data-driven R&D Autobahn to Cures”. EVOpanOmics involves the innovative use of genomics, transcriptomics, proteomics, and phenotypic data in an integrated fashion. Evotec has established high-throughput transcriptomics and proteomics technologies, which can be used as unbiased read-outs in drug discovery and development. EVOpanHunter is Evotec’s proprietary, integrated, user-centred bioinformatics platform which facilitates the analysis of PanOmics data integrated with other metadata sets. The combination of EVOpanOmics and EVOpanHunter on an integrated drug discovery and development platform is a game changer for data-driven approaches to highly effective personalised medicine.
During the first quarter 2022 conference call on Wednesday, 11 May 2022, Evotec will provide information regarding this partnership.
Conference call details
Date: Wednesday, 11 May 2022
Time: 02.00 pm CEST (08.00 am EDT, 01.00 pm BST)
From Germany: +49 69 20 17 44 220
From France: +33 170 709 502
From Italy: +39 023 600 6663
From UK: +44 20 3009 2470
From USA: +1 877 423 0830
Access Code: 53333776#
A simultaneous slide presentation for participants dialling in via phone is available at https://www.webcast-eqs.com/evotec20220511/no-audio.
FORWARD-LOOKING STATEMENTS
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “should,” “target,” “would” and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec’s expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.